苏州泽璟生物制药股份有限公司 股东会议事规则（草案） （H 股发行并上市后适用） 二〇二五年十一月 | | | | 第一章 | 总 则 | 1 | | --- | --- | --- | | 第二章 | 股东会的职权 | 2 | | 第三章 | 股东会的授权 | 3 | | 第四章 | 股东会会议制度 | 4 | | 第五章 | 股东会的召集 | 5 | | 第六章 | 股东会的提案与通知 | 6 | | 第七章 | 股东会的召开 | 8 | | 第八章 | 股东会的表决和决议 | 12 | | 第九章 | 会议记录 | 16 | | 第十章 | 附 则 | 17 | 苏州泽璟生物制药股份有限公司 股东会议事规则 第一章 总 则 合法、有效持有公司股份的股东均有权出席或委托代理人出席 股东会，并依法享有知情权、发言权、质询权和表决权等各项 股东权利。出席股东会的股东及股东代理人，应当遵守相关法 规、公司股票上市地证券监管规则、公司章程和本议事规则的 规定，自觉维护会议秩序，不得侵犯其他股东的合法权益。 1 第一条 为了进一步规范苏州泽璟生物制药股份有限公司（以下简称 "公司"）行为，保障公司股东会能够依法行使 ...

苏州泽璟生物制药股份有限公司（草案） 信息披露管理制度 （H 股发行并上市后适用） 二〇二五年十一月 1 第一章 总 则 第二章 信息披露的基本原则和一般规定 第一节 基本原则 第四条 信息披露义务人应当及时依法履行信息披露义务，披露的信息应 当真实、准确、完整，简明清晰、通俗易懂，不得有虚假记载、 误导性陈述或者重大遗漏。信息披露义务人披露的信息应当同时 2 第一条 为进一步提高苏州泽璟生物制药股份有限公司（以下简称"公 司"）的信息披露质量，规范公司的信息披露行为，保护投资者 的合法权益，根据《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司信息披露管理办法》《上海证券交易所科创板 股票上市规则》《香港联合交易所有限公司证券上市规则》（以下 简称"《香港上市规则》"，其中"香港联合交易所有限公司"以 下简称"香港联交所"）、《证券及期货条例》（以下简称"《条 例》"、《内幕消息披露指引》（以下简称"《指引》"）等法律、法 规、部门规章、规范性文件以及《苏州泽璟生物制药股份有限公 司章程》（以下简称"公司章程"）等相关制度规定，结合公司 实际情况，制定本制度。 第二条 本制度所称"信息披露"是指公 ...

泽璟制药：拟发行H股股票并在香港联交所上市。 ...

格隆汇11月14日丨泽璟制药(688266.SH)公布，为满足公司国际化战略及海外业务布局需要，提升公司 国际品牌知名度，增强公司综合竞争力，公司拟发行境外上市股份(H股)并申请在香港联合交易所有限 公司(简称"香港联交所")主板挂牌上市。 ...

Core Viewpoint - Suzhou Zelgen Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of injectable ZG006 in combination with etoposide and cisplatin for advanced neuroendocrine cancer [2][5] Group 1: Drug Information - ZG006 (INN name: alveltamig) is a trispecific antibody drug developed through the company's dual/multi-specific antibody research platform [3] - ZG006 has received clinical trial permits from both the FDA in the United States and the NMPA in China, and has been designated as a breakthrough therapy by the NMPA and an orphan drug by the FDA [3] - ZG006 targets two different DLL3 epitopes and CD3, acting as a T-cell engager that connects T-cells to tumor cells, showing significant tumor suppression in preclinical studies [3] Group 2: Clinical Trial Approval - The clinical trial approval for ZG006 in combination with etoposide and cisplatin is specifically for advanced neuroendocrine cancer [2] - The approval is not expected to have a significant impact on the company's recent performance due to the lengthy and uncertain nature of drug development [2][5] Group 3: Recent Developments - The company presented clinical research data and updates on ZG006 and ZG005 at the 2025 European Society for Medical Oncology (ESMO) annual meeting [4]

Group 1: Company Performance - SMIC reported a revenue of 17.162 billion yuan in Q3 2025, a year-on-year increase of 9.9%, with a net profit of 1.51 billion yuan, up 43.1% year-on-year. For the first three quarters, revenue reached 49.51 billion yuan, growing 18.2%, and net profit was 3.81 billion yuan, an increase of 41.1% year-on-year [1] - BoRui Pharma's BGM1812 injection has received clinical trial approval for weight loss indications, with no similar targeted formulations approved globally [2] - Li Zhong Group's subsidiaries received project confirmations for aluminum alloy wheels from major international automotive manufacturers, with expected total sales of approximately 1.135 billion yuan [4] Group 2: Corporate Actions - Kanda New Materials announced the termination of the acquisition of equity in North One Semiconductor due to unmet progress expectations and lack of consensus among parties [3] - Lide Man plans to acquire 70% of Xiansheng Xiangrui for 1.733 billion yuan, aiming to enter the bioproducts industry [9] - Arctech's controlling shareholder CSIQ expects total revenue of 1.3 to 1.5 billion USD in Q4 2025, with a gross margin of 14% to 16% [6] Group 3: Market Activity - Taihe Technology's VC project phase two construction will be adjusted based on phase one market expansion, indicating some uncertainty [5] - Hezhong China has experienced significant stock price fluctuations, with a cumulative increase of 230.84% over 12 out of 13 trading days, leading to potential application for trading suspension if abnormal price increases continue [7][8]

Core Points - Zai Jian Pharmaceutical has received approval from the National Medical Products Administration for a clinical trial of ZG006 in combination with Etoposide and Cisplatin for advanced neuroendocrine carcinoma [2] Group 1 - The clinical trial approval is a significant milestone for Zai Jian Pharmaceutical, indicating progress in its drug development pipeline [2] - The combination therapy aims to address a critical need in the treatment of advanced neuroendocrine cancer, which has limited treatment options [2]

Core Viewpoint - ZaiJing Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its drug ZG006 in combination with Etoposide and Cisplatin for advanced neuroendocrine cancer [1] Group 1: Company Developments - ZG006 is a trispecific antibody drug developed through the company's dual/multi-specific antibody research platform [1] - The drug has received clinical trial approval from both the US FDA and China's NMPA, and has been included in the breakthrough therapy category by the National Medical Products Administration [1] - ZG006 has also been granted orphan drug designation by the US FDA [1]

证券代码：688266 证券简称：泽璟制药 公告编号：2025-043 苏州泽璟生物制药股份有限公司 关于自愿披露注射用 ZG006 与依托泊苷及顺铂联用 获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 苏州泽璟生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药物临床试验批准通知书》， 注射用 ZG006 与依托泊苷及顺铂联合用于晚期神经内分泌癌的临床试验获得批 准。 本次临床试验获批事项对公司近期业绩不会产生重大影响。由于药品的研发 周期长、审批环节多、研发投入大，容易受到一些不确定性因素的影响，敬请广 大投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 苏州泽璟生物制药股份有限公司董事会 一、药品基本情况 二、药品相关情况 ZG006（INN 名：alveltamig）是公司通过其双/多特异性抗体研发平台开发 的一个三特异性抗体药物，已获得美国 FDA 和中国 NMPA 临床试验许可，并已 分别被国家 ...

Core Viewpoint - Zai Lab has received approval from the National Medical Products Administration for clinical trials of ZG006 in combination with etoposide and cisplatin for advanced neuroendocrine carcinoma, marking a significant milestone for the company's innovative drug development [1][2]. Group 1: Drug Development - ZG006 (INN: alveltamig) is a trispecific antibody drug developed through the company's dual/multi-specific antibody platform, which has received clinical trial approvals from both the FDA and NMPA [1]. - ZG006 has been designated as a breakthrough therapy by the NMPA and has received orphan drug designation from the FDA, highlighting its potential in treating rare diseases [1]. - ZG006 is the first-in-class molecule targeting DLL3, with the potential to become a best-in-class therapy due to its unique mechanism of action [1]. Group 2: Mechanism of Action - ZG006 binds to different DLL3 epitopes on tumor cells and the CD3 region on T cells, effectively bridging the two and enhancing T cell-mediated tumor cell destruction [2]. - Preclinical studies have demonstrated significant tumor suppression in mouse models, with a notable proportion of tumors completely regressing, indicating ZG006's strong anti-tumor efficacy [2].